Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorYalcin, Serap
dc.contributor.authorErkan, Mert
dc.contributor.authorUnsoy, Gozde
dc.contributor.authorParsian, Maryam
dc.contributor.authorKleeff, Jorg
dc.contributor.authorGunduz, Ufuk
dc.date.accessioned2019-11-24T20:59:03Z
dc.date.available2019-11-24T20:59:03Z
dc.date.issued2014
dc.identifier.issn0753-3322
dc.identifier.issn1950-6007
dc.identifier.urihttps://dx.doi.org/10.1016/j.biopha.2014.07.003
dc.identifier.urihttps://hdl.handle.net/20.500.12513/3207
dc.descriptionWOS: 000342668300009en_US
dc.descriptionPubMed ID: 25108345en_US
dc.description.abstractGemcitabine is an anticancer drug used in the treatment of different cancer types, including pancreatic ductal adenocarcinoma. The maximum tolerated dose in humans is restricted by its side effects on healty cells. Furthermore, the fibrotic stroma produced by the pancreatic stellate cells prevents effective delivery of chemotherapeutic agents providing a safe-haven for the cancer cells. This becomes more of a problem considering the short half-life of this drug. Magnetic nanoparticle-based targeted drug delivery systems are a promising alternative to overcome the limitations of classical chemotherapies. The aim of this study is to obtain an effective targeted delivery system for gemcitabine using magnetic nanoparticles (MNPs) and all-trans retinoic acid (ATRA). This dual approach targets the tumor cells and its infrastructure - stellate cells - simultaneously. Gemcitabine and ATRA were loaded onto the PAMAM dendrimer-coated magnetic nanoparticles (DcMNPs), which were synthesized and characterized previously. Drug loading and release characteristics, and stability of the nanoparticles were investigated. Gemcitabine and ATRA loaded MNPs are efficiently taken up by pancreatic cancer and stellate cells successfully targeting and eliminating both cells. Results of this study can provide new insights on pancreatic cancer therapy where tumor is seen as a system with its stroma insead of epithelial cells alone. (C) 2014 Elsevier Masson SAS. All rights reserved.en_US
dc.description.sponsorshipTUBITAK (The Scientific And Technological Research Council of Turkey)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [2219]en_US
dc.description.sponsorshipThis study is supported by TUBITAK (The Scientific And Technological Research Council of Turkey)-2219 International Postdoctoral Research Fellowship Programme.en_US
dc.language.isoengen_US
dc.publisherELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERen_US
dc.relation.isversionof10.1016/j.biopha.2014.07.003en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGemcitabineen_US
dc.subjectRetinoic aciden_US
dc.subjectPAMAM dendrimeren_US
dc.subjectNanoparticleen_US
dc.subjectPancreatic canceren_US
dc.subjectStellate cell linesen_US
dc.titleEffect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell linesen_US
dc.typearticleen_US
dc.relation.journalBIOMEDICINE & PHARMACOTHERAPYen_US
dc.contributor.departmentKırşehir Ahi Evran Üniversitesi, Mühendislik-Mimarlık Fakültesi, Gıda Mühendisliği Bölümüen_US
dc.identifier.volume68en_US
dc.identifier.issue6en_US
dc.identifier.startpage737en_US
dc.identifier.endpage743en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster